Global Liquid Biopsy Markets 2019-2023 By Cancer Type By Diagnosis, Monitoring & Recurrence Testing - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--Nov 12, 2018--The “Liquid Biopsy Markets By Cancer Type By Diagnosis, Monitoring & Recurrence Testing. 2019-2023 W. Historical Data Including Screening Market Potential Size With Executive And Consultant Guides” report has been added to ResearchAndMarkets.com’s offering.
The Diagnostic, Therapy Monitoring, Recurrence Monitoring and Screening Test opportunities are explored.
A revolution in cancer diagnostics is occurring using in vitro blood testing to identify cancer DNA. The technology creates new markets for cancer screening tests.
GRAIL, a new company with impressive backing, has announced a single blood test to detect all cancers. The company is now working on a 10,000-plus subject study, called the Circulating Cell-Free Genome Atlas (CCGA) to help identify cancer early. The technology is moving faster than the market.
New technology that definitively identifies disease conditions from blood samples is poised to replace expensive invasive surgical biopsy procedures. The market is still in its infancy but has outstanding growth potential. The impact on the health care industry is enormous.
The report forecasts the market size out to 2023. In addition, the report looks at potential market sizes by country, by cancer and by the three different opportunities: detection, management and screening.
Circulating Tumor Cells? Cell Free DNA? Exosomes? Find out about the technology in readily understood terms that explain the jargon. Find the opportunities and the pitfalls. Understand growth expectations and the ultimate potential market size.
Key Topics Covered:
1. Introduction and Market Definition
2. Market Overview
3. Market Trends
4. Liquid Biopsy Recent Developments
5. Country Market Sizes - North America
6. Country Markets - Europe
7. Country Markets - Asia Pacific
8. Country Markets - Latin America, Africa & The Middle East
9. Global Market Summary
10. Potential Market Opportunity Sizes
Companies MentionedAgena Bioscience Angle plc ApoCell Bio Cartis Bio-Techne Bioarray Genetics Biocept Biodesix Inc. BioFluidica Boreal Genomics CellMax Life CytoTrack Diagnologix LLC Epic Sciences Exosome Diagnostics Exosome Sciences Fluidigm Corp HansaBiomed Horizon Discovery iCellate Illumina MDx Health miR Scientific Molecular MD Myriad Genetics Natera New Oncology Oncocyte OncoDNA Roche Diagnostics Silicon Biosystems SRI International Sysmex Inostics Thermo Fisher Trovagene
For more information about this report visit https://www.researchandmarkets.com/research/9bl6vm/global_liquid?w=4
View source version on businesswire.com:https://www.businesswire.com/news/home/20181112005363/en/
Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics:Diagnostics,In Vitro Diagnostics
INDUSTRY KEYWORD: HEALTH MEDICAL DEVICES
SOURCE: Research and Markets
Copyright Business Wire 2018.
PUB: 11/12/2018 07:36 AM/DISC: 11/12/2018 07:36 AM